{
    "biomarker_id": "AN6315-1",
    "biomarker_canonical_id": "AN6315",
    "condition": {
        "recommended_name": {
            "id": "DOID:1324",
            "resource": "Disease Ontology",
            "url": "https://disease-ontology.org/term/DOID:1324",
            "name": "lung cancer",
            "description": "A respiratory system cancer that is located_in the lung."
        },
        "synonyms": [
            {
                "id": "MONDO:0008903",
                "resource": "MONDO",
                "url": "https://monarchinitiative.org/disease/MONDO:0008903",
                "name": "lung cancer",
                "description": "A malignant neoplasm involving the lung."
            },
            {
                "id": "MONDO:0008903",
                "resource": "MONDO",
                "url": "https://monarchinitiative.org/disease/MONDO:0008903",
                "name": "adenocarcinoma of lung, response to tyrosine kinase inhibitor in, autosomal dominant, somatic mutation",
                "description": ""
            },
            {
                "id": "MONDO:0008903",
                "resource": "MONDO",
                "url": "https://monarchinitiative.org/disease/MONDO:0008903",
                "name": "adenocarcinoma of lung, somatic",
                "description": ""
            },
            {
                "id": "MONDO:0008903",
                "resource": "MONDO",
                "url": "https://monarchinitiative.org/disease/MONDO:0008903",
                "name": "cancer of lung",
                "description": ""
            },
            {
                "id": "MONDO:0008903",
                "resource": "MONDO",
                "url": "https://monarchinitiative.org/disease/MONDO:0008903",
                "name": "lung cancer",
                "description": ""
            },
            {
                "id": "MONDO:0008903",
                "resource": "MONDO",
                "url": "https://monarchinitiative.org/disease/MONDO:0008903",
                "name": "lung cancer, protection against, autosomal dominant, somatic mutation",
                "description": ""
            },
            {
                "id": "MONDO:0008903",
                "resource": "MONDO",
                "url": "https://monarchinitiative.org/disease/MONDO:0008903",
                "name": "lung cancer, resistance to, autosomal dominant, somatic mutation",
                "description": ""
            },
            {
                "id": "MONDO:0008903",
                "resource": "MONDO",
                "url": "https://monarchinitiative.org/disease/MONDO:0008903",
                "name": "lung cancer, somatic",
                "description": ""
            },
            {
                "id": "MONDO:0008903",
                "resource": "MONDO",
                "url": "https://monarchinitiative.org/disease/MONDO:0008903",
                "name": "lung cancer, susceptibility to, autosomal dominant, somatic mutation",
                "description": ""
            },
            {
                "id": "MONDO:0008903",
                "resource": "MONDO",
                "url": "https://monarchinitiative.org/disease/MONDO:0008903",
                "name": "malignant lung neoplasm",
                "description": ""
            },
            {
                "id": "MONDO:0008903",
                "resource": "MONDO",
                "url": "https://monarchinitiative.org/disease/MONDO:0008903",
                "name": "malignant lung tumor",
                "description": ""
            },
            {
                "id": "MONDO:0008903",
                "resource": "MONDO",
                "url": "https://monarchinitiative.org/disease/MONDO:0008903",
                "name": "malignant lung tumour",
                "description": ""
            },
            {
                "id": "MONDO:0008903",
                "resource": "MONDO",
                "url": "https://monarchinitiative.org/disease/MONDO:0008903",
                "name": "malignant neoplasm of lung",
                "description": ""
            },
            {
                "id": "MONDO:0008903",
                "resource": "MONDO",
                "url": "https://monarchinitiative.org/disease/MONDO:0008903",
                "name": "malignant neoplasm of the lung",
                "description": ""
            },
            {
                "id": "MONDO:0008903",
                "resource": "MONDO",
                "url": "https://monarchinitiative.org/disease/MONDO:0008903",
                "name": "malignant tumor of lung",
                "description": ""
            },
            {
                "id": "MONDO:0008903",
                "resource": "MONDO",
                "url": "https://monarchinitiative.org/disease/MONDO:0008903",
                "name": "malignant tumor of the lung",
                "description": ""
            },
            {
                "id": "MONDO:0008903",
                "resource": "MONDO",
                "url": "https://monarchinitiative.org/disease/MONDO:0008903",
                "name": "malignant tumour of lung",
                "description": ""
            },
            {
                "id": "MONDO:0008903",
                "resource": "MONDO",
                "url": "https://monarchinitiative.org/disease/MONDO:0008903",
                "name": "malignant tumour of the lung",
                "description": ""
            },
            {
                "id": "MONDO:0008903",
                "resource": "MONDO",
                "url": "https://monarchinitiative.org/disease/MONDO:0008903",
                "name": "nonsmall cell lung cancer, response to tyrosine kinase inhibitor in, autosomal dominant, somatic mutation",
                "description": ""
            },
            {
                "id": "MONDO:0008903",
                "resource": "MONDO",
                "url": "https://monarchinitiative.org/disease/MONDO:0008903",
                "name": "nonsmall cell lung cancer, somatic",
                "description": ""
            },
            {
                "id": "MONDO:0008903",
                "resource": "MONDO",
                "url": "https://monarchinitiative.org/disease/MONDO:0008903",
                "name": "nonsmall cell lung cancer, susceptibility to, autosomal dominant, somatic mutation",
                "description": ""
            },
            {
                "id": "MONDO:0012159",
                "resource": "MONDO",
                "url": "https://monarchinitiative.org/disease/MONDO:0012159",
                "name": "lung cancer susceptibility 1",
                "description": ""
            },
            {
                "id": "MONDO:0012159",
                "resource": "MONDO",
                "url": "https://monarchinitiative.org/disease/MONDO:0012159",
                "name": "LNCR1",
                "description": ""
            },
            {
                "id": "MONDO:0012159",
                "resource": "MONDO",
                "url": "https://monarchinitiative.org/disease/MONDO:0012159",
                "name": "lung cancer susceptibility",
                "description": ""
            },
            {
                "id": "MONDO:0012159",
                "resource": "MONDO",
                "url": "https://monarchinitiative.org/disease/MONDO:0012159",
                "name": "lung cancer susceptibility 1",
                "description": ""
            },
            {
                "id": "MONDO:0012942",
                "resource": "MONDO",
                "url": "https://monarchinitiative.org/disease/MONDO:0012942",
                "name": "lung cancer susceptibility 3",
                "description": ""
            },
            {
                "id": "MONDO:0012942",
                "resource": "MONDO",
                "url": "https://monarchinitiative.org/disease/MONDO:0012942",
                "name": "LNCR3",
                "description": ""
            },
            {
                "id": "MONDO:0012942",
                "resource": "MONDO",
                "url": "https://monarchinitiative.org/disease/MONDO:0012942",
                "name": "lung cancer susceptibility 3",
                "description": ""
            },
            {
                "id": "MONDO:0012955",
                "resource": "MONDO",
                "url": "https://monarchinitiative.org/disease/MONDO:0012955",
                "name": "lung cancer susceptibility 4",
                "description": ""
            },
            {
                "id": "MONDO:0012955",
                "resource": "MONDO",
                "url": "https://monarchinitiative.org/disease/MONDO:0012955",
                "name": "LNCR4",
                "description": ""
            },
            {
                "id": "MONDO:0012955",
                "resource": "MONDO",
                "url": "https://monarchinitiative.org/disease/MONDO:0012955",
                "name": "lung cancer susceptibility 4",
                "description": ""
            },
            {
                "id": "MONDO:0013631",
                "resource": "MONDO",
                "url": "https://monarchinitiative.org/disease/MONDO:0013631",
                "name": "lung cancer susceptibility 5",
                "description": ""
            },
            {
                "id": "MONDO:0013631",
                "resource": "MONDO",
                "url": "https://monarchinitiative.org/disease/MONDO:0013631",
                "name": "LNCR5",
                "description": ""
            },
            {
                "id": "MONDO:0013631",
                "resource": "MONDO",
                "url": "https://monarchinitiative.org/disease/MONDO:0013631",
                "name": "lung cancer susceptibility 5",
                "description": ""
            },
            {
                "id": "MIM:211980",
                "resource": "MIM",
                "url": "https://www.omim.org/entry/211980",
                "name": "Lung cancer",
                "description": "Lung cancer"
            }
        ],
        "id": "DOID:1324"
    },
    "biomarker_component": [
        {
            "biomarker": "increased KRT19 level",
            "assessed_biomarker_entity_id": "P08727-1",
            "assessed_entity_type": "protein",
            "assessed_biomarker_entity": {
                "recommended_name": "Keratin, type I cytoskeletal 19",
                "synonyms": [
                    {
                        "synonym": "Keratin-19"
                    },
                    {
                        "synonym": "K19"
                    },
                    {
                        "synonym": "Cytokeratin-19"
                    },
                    {
                        "synonym": "CK-19"
                    }
                ]
            },
            "specimen": [
                {
                    "name": "blood",
                    "namespace": "UBERON",
                    "id": "0000178",
                    "url": "http://purl.obolibrary.org/obo/UBERON_0000178",
                    "loinc_code": ""
                }
            ],
            "evidence_source": [
                {
                    "id": "AN6315-1",
                    "database": "BiomarkerKB",
                    "url": "https://biomarkerkb.org/biomarker/AN6315-1"
                },
                {
                    "id": "16033098",
                    "database": "PubMed",
                    "url": "https://glygen.org/publication/PubMed/16033098",
                    "tags": [
                        "assessed_biomarker_entity",
                        " biomarker",
                        " specimen"
                    ],
                    "evidence_list": [
                        {
                            "evidence": "Tumor marker serum levels were related to histological type and tumor extension, with ProGRP being the most sensitive marker in SCLC, CEA in adenocarcinomas and CYFRA 21-1 in squamous tumors. The most sensitive combinations of tumor markers were ProGRP and NSE in SCLC (88%), and CEA plus CYFRA in NSCLC (82%). In summary, ProGRP is the tumor marker of choice in SCLC and NSE is a complementary tumor marker in this histological type."
                        }
                    ]
                },
                {
                    "id": "7541742",
                    "database": "PubMed",
                    "url": "https://glygen.org/publication/PubMed/7541742",
                    "tags": [
                        "assessed_biomarker_entity",
                        " biomarker",
                        " specimen"
                    ],
                    "evidence_list": [
                        {
                            "evidence": "Cyfra 21-1 levels were significantly higher in advanced NSCLC than in early-stage disease. All 29 patients with serum concentrations > 32 ng/mL had stage IIIB-IV and only one of 14 patients with stage I-II disease had Cyfra 21-1 level > 18 ng/mL. In the multivariate analysis of survival, Cyfra 21-1 was an independent prognostic factor along with performance status and disease stage in NSCLC. Cyfra 21-1 is a sensitive and specific tumor marker of NSCLC, especially of squamous cell subtype. It also reflects the extent of the disease and has an independent prognostic role along with performance status and disease stage in NSCLC. Cyfra 21-1 was an independent prognostic factor along with performance status and disease stage in NSCLC."
                        }
                    ]
                }
            ]
        }
    ],
    "best_biomarker_role": [
        {
            "role": "prognostic"
        }
    ],
    "evidence_source": [
        {
            "id": "AN6315-1",
            "database": "BiomarkerKB",
            "url": "https://biomarkerkb.org/biomarker/AN6315-1"
        },
        {
            "id": "16033098",
            "database": "PubMed",
            "url": "https://glygen.org/publication/PubMed/16033098",
            "tags": [
                "best_biomarker_role",
                " condition"
            ],
            "evidence_list": [
                {
                    "evidence": "Tumor marker serum levels were related to histological type and tumor extension, with ProGRP being the most sensitive marker in SCLC, CEA in adenocarcinomas and CYFRA 21-1 in squamous tumors. The most sensitive combinations of tumor markers were ProGRP and NSE in SCLC (88%), and CEA plus CYFRA in NSCLC (82%). In summary, ProGRP is the tumor marker of choice in SCLC and NSE is a complementary tumor marker in this histological type."
                }
            ]
        },
        {
            "id": "7541742",
            "database": "PubMed",
            "url": "https://glygen.org/publication/PubMed/7541742",
            "tags": [
                "best_biomarker_role",
                " condition"
            ],
            "evidence_list": [
                {
                    "evidence": "Cyfra 21-1 levels were significantly higher in advanced NSCLC than in early-stage disease. All 29 patients with serum concentrations > 32 ng/mL had stage IIIB-IV and only one of 14 patients with stage I-II disease had Cyfra 21-1 level > 18 ng/mL. In the multivariate analysis of survival, Cyfra 21-1 was an independent prognostic factor along with performance status and disease stage in NSCLC. Cyfra 21-1 is a sensitive and specific tumor marker of NSCLC, especially of squamous cell subtype. It also reflects the extent of the disease and has an independent prognostic role along with performance status and disease stage in NSCLC. Cyfra 21-1 was an independent prognostic factor along with performance status and disease stage in NSCLC."
                }
            ]
        }
    ],
    "crossref": [
        {
            "id": "AN6315-1",
            "database": "BiomarkerKB",
            "url": "https://biomarkerkb.org/biomarker/AN6315-1",
            "categories": [
                "Biomarkers"
            ]
        }
    ],
    "citation": [
        {
            "title": "Pro-gastrin-releasing peptide (proGRP) in patients with benign and malignant diseases: comparison with CEA, SCC, CYFRA 21-1 and NSE in patients with lung cancer.",
            "journal": "Anticancer research",
            "authors": "Molina R, Auge JM, Filella X, Vinolas N, Alicarte J, Domingo JM, Ballesta AM",
            "date": "2005",
            "reference": [
                {
                    "type": "PubMed",
                    "id": "16033098",
                    "url": "https://glygen.org/publication/PubMed/16033098"
                }
            ],
            "evidence": [
                {
                    "id": "AN6314-3",
                    "database": "BiomarkerKB",
                    "url": "https://biomarkerkb.org/biomarker/AN6315-1"
                }
            ]
        },
        {
            "title": "Cyfra 21-1 as a biologic marker of non-small cell lung cancer. Evaluation of sensitivity, specificity, and prognostic role.",
            "journal": "Chest",
            "authors": "Wieskopf B, Demangeat C, Purohit A, Stenger R, Gries P, Kreisman H, Quoix E",
            "date": "1995",
            "reference": [
                {
                    "type": "PubMed",
                    "id": "7541742",
                    "url": "https://glygen.org/publication/PubMed/7541742"
                }
            ],
            "evidence": [
                {
                    "id": "AN6315-1",
                    "database": "BiomarkerKB",
                    "url": "https://biomarkerkb.org/biomarker/AN6315-1"
                }
            ]
        }
    ],
    "section_stats": [
        {
            "table_id": "biomarker_component",
            "table_stats": [
                {
                    "field": "total",
                    "count": 1
                }
            ],
            "sort_fields": [
                "biomarker",
                "assessed_biomarker_entity_id",
                "assessed_entity_type",
                "assessed_biomarker_entity.recommended_name"
            ]
        },
        {
            "table_id": "citation",
            "table_stats": [
                {
                    "field": "total",
                    "count": 2
                }
            ],
            "sort_fields": [
                "title",
                "journal",
                "authors",
                "date"
            ]
        }
    ]
}